Nasdaq · Healthcare
BIOMARIN PHARMACEUTICAL INC (BMRN)
As-reported financials and recent SEC filings for BIOMARIN PHARMACEUTICAL INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.22B
Net income
$348.9M
Net margin
10.8%
Diluted EPS
$1.80
ROE
5.7%
P/E (TTM)
42.4×
Market cap
$11.40B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Gross profit | $2.50B | $2.27B | $1.89B | $1.59B | $1.38B |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | $-82.3M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | $-64.1M |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →Go deeper on BMRN
Search BIOMARIN PHARMACEUTICAL INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.